October 13, 2020 | Abby Phillips

DURHAM —  Emergo Therapeutics, a biopharmaceutical startup founded by serial entrepreneur Moise Khayrallah, has raised roughly $3.5 million in equity, according to a recent securities filing.

Seventy seven investors contributed to the round, which is capped at around $5 million.

Proceeds will be used for working capital, the filing noted, “which may include normal compensation to executive officers.”

Emergo is developing a single drug candidate, norketotifen, for treating flu and flu-like illnesses. The compound works by modulating the immune system’s response to viral infection.

Khayrallah and Robin Hyde-DeRuyscher, Emergo’s co-founder and chief scientific officer, positioned the company for the venture round with the help of a $75,000 Company Inception Loan from the North Carolina Biotechnology Center in 2017.

It has since raised around $15 million to date, including this latest raise.

Comments are closed.

« Need car insurance? Want to sell your vehicle? Need warranty? Get Spiffy can help
IBM and The Climate Service to Work Together with Financial Institutions and Corporations to Assess the Cost of Climate Risk »